Angiotensin-converting enzyme (ACE) inhibitor (IC50 = 0.022µM) which also inhibits LTA4 hydrolase in a reversible and competitive manner.
Shows antihypertensive and vasodilatory effects
Orally active.
Recently studied as part of COVID-19 compound repurposing.
Solubility & Handling
Storage instructions
+4°C
Solubility overview
Soluble in water (100mM) and in DMSO (100mM)
Handling
In aqueous solution, Captopril undergoes a free radical dimerisation to form captopril disulfide. To delay oxidation, use a lower pH, degas solution, minimize headspace, increase the concentration or incorporate a chelating agent or antioxidant.
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY)
Zhang et al (1996) Clin Exp Hypertens 18(2) : 201-26